GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » Beneish M-Score

Zosano Pharma (Zosano Pharma) Beneish M-Score : 0.00 (As of May. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Zosano Pharma's Beneish M-Score or its related term are showing as below:

During the past 10 years, the highest Beneish M-Score of Zosano Pharma was 0.00. The lowest was 0.00. And the median was 0.00.


Zosano Pharma Beneish M-Score Historical Data

The historical data trend for Zosano Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zosano Pharma Beneish M-Score Chart

Zosano Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -10.38

Zosano Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -10.38 -5.04

Competitive Comparison of Zosano Pharma's Beneish M-Score

For the Biotechnology subindustry, Zosano Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zosano Pharma's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zosano Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zosano Pharma's Beneish M-Score falls into.



Zosano Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zosano Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3221+0.528 * -3.3396+0.404 * 2.4686+0.892 * 1.3672+0.115 * 0.3343
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7149+4.679 * -0.088939-0.327 * 1.3782
=-5.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar22) TTM:Last Year (Mar21) TTM:
Total Receivables was $0.11 Mil.
Revenue was 0.132 + 0.087 + 0.252 + 0.188 = $0.66 Mil.
Gross Profit was 0.046 + -0.005 + -0.088 + -0.014 = $-0.06 Mil.
Total Current Assets was $15.63 Mil.
Total Assets was $26.45 Mil.
Property, Plant and Equipment(Net PPE) was $10.36 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.57 Mil.
Selling, General, & Admin. Expense(SGA) was $10.68 Mil.
Total Current Liabilities was $9.73 Mil.
Long-Term Debt & Capital Lease Obligation was $2.66 Mil.
Net Income was -33.409 + -6.971 + -8.668 + -6.144 = $-55.19 Mil.
Non Operating Income was -25.961 + -0.002 + -0.057 + 1.85 = $-24.17 Mil.
Cash Flow from Operations was -8.54 + -5.831 + -6.315 + -7.984 = $-28.67 Mil.
Total Receivables was $0.24 Mil.
Revenue was 0.258 + 0.224 + 0 + 0 = $0.48 Mil.
Gross Profit was 0.096 + 0.053 + 0 + 0 = $0.15 Mil.
Total Current Assets was $28.47 Mil.
Total Assets was $65.71 Mil.
Property, Plant and Equipment(Net PPE) was $36.78 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.69 Mil.
Selling, General, & Admin. Expense(SGA) was $10.92 Mil.
Total Current Liabilities was $14.41 Mil.
Long-Term Debt & Capital Lease Obligation was $7.93 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.107 / 0.659) / (0.243 / 0.482)
=0.162367 / 0.504149
=0.3221

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.149 / 0.482) / (-0.061 / 0.659)
=0.309129 / -0.092564
=-3.3396

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (15.632 + 10.358) / 26.445) / (1 - (28.473 + 36.779) / 65.71)
=0.017206 / 0.00697
=2.4686

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.659 / 0.482
=1.3672

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.689 / (1.689 + 36.779)) / (1.566 / (1.566 + 10.358))
=0.043907 / 0.131332
=0.3343

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10.675 / 0.659) / (10.921 / 0.482)
=16.198786 / 22.657676
=0.7149

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.662 + 9.73) / 26.445) / ((7.934 + 14.408) / 65.71)
=0.468595 / 0.340009
=1.3782

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-55.192 - -24.17 - -28.67) / 26.445
=-0.088939

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zosano Pharma has a M-score of -5.04 suggests that the company is unlikely to be a manipulator.


Zosano Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zosano Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zosano Pharma (Zosano Pharma) Business Description

Traded in Other Exchanges
N/A
Address
34790 Ardentech Court, Fremont, CA, USA, 94555
Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
Executives
Christine Matthews officer: Chief Financial Officer C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo director, officer: Chief Executive Officer C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman officer: VP, Clinical Dev & Med Affairs INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang director C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse director 3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis officer: See Remarks C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos director 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Zosano Pharma (Zosano Pharma) Headlines

From GuruFocus

Zosano Pharma Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-23-2022

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

By GuruFocusNews GuruFocusNews 06-02-2022

Zosano Pharma Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-12-2022